CLL Treatment Evolution: Rethinking Monotherapy vs Combination Strategies in the Era of Next-Generation BTK Inhibitors

CLL Treatment Evolution: Rethinking Monotherapy vs Combination Strategies in the Era of Next-Generation BTK Inhibitors

The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians managing this increasingly complex disease. In this episode of the FLASCO OncoPod, FLASCO President Edgardo Santos, MD, FACP, FASCO, sits down with renowned CLL expert Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center to discuss how advances in targeted therapies are reshaping treatment decisions across the CLL continuum. Together, they explore the evolution of CLL care from chemoimmunotherapy to modern treatment approaches centered around BTK inhibitors, BCL2 inhibitors, and anti-CD20 monoclonal antibodies. The conversation examines how molecular and genetic risk factors, including IGHV mutation status, TP53 abnormalities, and cytogenetic findings, influence first-line treatment selection and long-term management strategies. Dr. Pinilla-Ibarz shares practical insights into the ongoing debate between fixed-duration combination regimens and continuous therapy approaches, highlighting the benefits, limitations, and patient-specific considerations that guide real-world clinical decision-making. The discussion also covers measurable residual disease (MRD), emerging MRD-guided treatment strategies, management of high-risk disease, sequencing therapies after relapse, and the growing role of next-generation BTK inhibitors. Looking ahead, the episode explores promising therapies on the horizon, including novel BTK degraders, next-generation BCL2 inhibitors, cellular therapies, and other innovative approaches that may further improve outcomes for patients living with CLL. Whether you are a hematologist, oncologist, advanced practice provider, or healthcare professional interested in the latest developments in blood cancers, this episode offers a comprehensive and clinically relevant update on where CLL treatment stands today and where the field is headed next.

What's New in Endometrial Cancer: Key Takeaways From SGO 2026

Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting. In this episode, Dr. Jordan reviews promising new therapies, including emerging antibody-drug conjugates and novel hormonal treatment combinations, highlights exciting clinical trial results, and discusses long-term follow-up data from the practice-changing RUBY trial. From breakthrough research to upcoming Phase III studies that may shape the future standard of care, this conversation provides oncology professionals with key insights into the rapidly evolving treatment landscape for advanced and recurrent endometrial cancer.

ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia

What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care? In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conversation about leadership, advocacy, and the launch of ASCO Edge, a new educational resource designed to help oncology professionals better understand the operational and business side of cancer care. Dr. Zon reflects on her professional journey from community oncology practice to serving as President of ASCO, sharing how early experiences shaped her passion for empowering clinicians with the tools needed to manage practices, navigate evolving healthcare systems, and advocate for both patients and providers. Together, they explore: • The inspiration behind ASCO Edge • Why business education matters in oncology • Challenges facing modern cancer care delivery • How oncology professionals can strengthen operational knowledge • The importance of state societies and collaborative advocacy • What clinicians, pharmacists, APPs, fellows, and practice leaders can gain from the platform Designed by oncology professionals for oncology professionals, ASCO Edge offers practical, on-demand learning modules focused on real-world scenarios impacting cancer care today. Learn more about FLASCO and upcoming educational initiatives at FLASCO.org [http://FLASCO.org] Get started with ASCO Edge today at https://www.asco.org/meetings-education/training-programs/asco-edge [https://www.asco.org/meetings-education/training-programs/asco-edge] #FLASCO #Oncology #ASCO #CancerCare #CommunityOncology #HealthcareLeadership #MedicalEducation #OncoPod #OncologyPodcast #PracticeManagement #CancerResearch #OncologyProfessionals

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls

In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology patients. Building on the diagnostic and acute management discussions from earlier segments, the panel explores key considerations that guide care beyond the initial presentation. Topics include the role of genetic and complement testing, how to interpret mutation findings, and the factors that influence decisions around the duration of complement inhibition therapy. Through real-world insights, the discussion highlights the complexity of identifying underlying triggers, including drug exposure and infection, and the importance of clinical judgment when determining whether and when treatment can be safely discontinued. The panel also addresses practical challenges, from variability in testing access to navigating uncertainty in cases without clear pathogenic mutations. Listen as the experts walk through how thoughtful, individualized decision-making can support recovery, preserve renal function, and optimize long-term outcomes for patients with aHUS.

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 2: Acute Management: TTP vs aHUS and Treatment Decisions

In this episode of the FLASCO OncoPod, Drs. Jaglal, Fu, and Shahzad explore the real-world challenges of managing suspected thrombotic microangiopathy (TMA) in oncology patients. Building on a complex multiple myeloma case introduced in Part 1, this segment focuses on acute decision-making in the hospital setting. The discussion highlights how to differentiate thrombotic thrombocytopenic purpura (TTP) from atypical hemolytic uremic syndrome (aHUS), when to initiate plasma exchange, and how clinicians approach complement inhibition in time-sensitive, high-stakes scenarios. Through expert insights and practical considerations, the panel walks through key diagnostic clues including peripheral smear findings, LDH elevation, and clinical presentation, while also addressing the realities of delayed lab results, treatment access, and institutional protocols. Listen in as they unpack how to act quickly, think critically, and navigate uncertainty to optimize outcomes in patients with suspected TMA.